“We are on track to deliver the majority of the anticipated $7.2 billion in total net cost savings from our productivity programs by 2026.”

In context

“e assets. As a result, we recorded approximately $4.4 billion of non-cash intangible asset impairments related to several medicines in development, as well as in-line products. It is important to note that one of the asset indications we deprioritized was dicitamab vedotin in bladder cancer, largely the result of the recently strong study readouts, expanded indications, and related higher long-term revenue projections for PADCEP. PADCEV is an asset we will continue to invest behind, thus diminishing the value of DV in bladder cancer. I will also mention while impairment decisions are based on current valuations of individual assets, overall, the Seagen portfolio is progressing ahead of our expectations. These decisions highlight our focus on delivering future growth as well as innovation. We are on track to deliver the majority of the anticipated $7.2 billion in total net cost savings from our productivity programs by 2026. We expect additional savings of $700 million in 2026 and $200 million in 2027 from phase one of the manufacturing program for a total of $1.5 billion in savings by 2027. In addition, we exceeded our savings target through 2025 from our cost realignment program. And as previously communicated, the R&D savings achieved in 2025 under the cost realignment program are expected to be reinvested in 2026 and are reflected in our 2026 R&D guidance range. We remain committed to achieving the expected $5.7 billion total net savings from our cost realignment program by 2026, at which time we will have met our savings commitment under the program. Going forward, we will continue to focus on identifying further productivity opportunities and efficiencies. Let me quickly touch upon our capital allocatio”